Clinical trials: Stroke/Brain Attack
Carotid Artery Diseases, Carotid Artery Stenosis
Timing Carotid Stent Clinical Study for the Treatment of Carotid Artery Stenosis（Timing Trial）
Evaluate the safety and efficacy of the Timing Carotid Stent for the treatment of carotid artery stenosis in patients.
- Conditions
- Carotid Artery Diseases, Carotid Artery Stenosis, Stroke, Ischemic Stroke
- Trial name
- NCT05574972
- Testing
- Timing Carotid Stent, Carotid Wallstent
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Suzhou Zenith Vascular SciTech Limited
Stroke, Sleep Apnea
Impact of Early Ventilation in Stroke Outcomes in Patients With Sleep Apnea After First Ever Stroke
To evaluate the impact of early ventilation in stroke outcomes in patients with sleep apnea and first ever stroke, 1 month after stroke.
- Trial name
- NCT04903951
- Testing
- Adaptive Servoventilation (ASV) therapy, Best medical treatment
- Where
- Portugal
- Volunteers
- 90 people
- Sponsor
- Philips Portuguesa S.A.
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Cerebral Infarction
Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)
Sarpogrelate (MCI-9042) is an antiplatelet drug that decreases 5-hydroxytryptamine (5-HT) levels in platelets via a blockade of 5-HT2 receptors; it has been used in atherosclerotic peripheral arterial disease.
- Trial name
- NCT00129805
- Testing
- MCI-9042, Aspirin
- Volunteers
- 1,510 people
- Sponsor
- Tanabe Pharma Corporation
Vascular Dementia
The Clinical Trial of Chinese Herbal Medicine SaiLuoTong Capsule
As a traditional Chinese medicine compound, SaiLuoTong capsule is proven to have beneficial effects on learning and memory ability in animal models of vascular dementia (VaD).
- Trial name
- NCT01978730
- Testing
- high dose group of SaiLuoTong capsule, low dose group of SaiLuoTong, the control group
- Where
- 16 sites in China
- Volunteers
- 372 people
- Sponsor
- Shineway Pharmaceutical Co.,Ltd
Aortic Stenosis
The PROTEMBO SF Trial
The PROTEMBO SF Trial is a prospective, observational, multi-center, intention-to-treat study of the safety and feasibility of the ProtEmbo Cerebral Protection System in subjects with severe symptomatic native aortic valve…
- Trial name
- NCT03325283
- Testing
- ProtEmbo Cerebral Protection System
- Where
- 2 sites in Ireland, Latvia
- Volunteers
- 5 people
- Sponsor
- Protembis GmbH
Prevention of Thromboembolic Events, Atrial Fibrillation
A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver Function
Researchers are looking for a better way to prevent the formation of blood clots in people who have or have had: an irregular and often rapid heartbeat a blocked blood flow to the heart a blocked or reduced blood flow to a part…
- Conditions
- Prevention of Thromboembolic Events, Atrial Fibrillation, Acute Myocardial Infarction, Non-cardioembolic Ischemic Stroke
- Trial name
- NCT05419635
- Testing
- Asundexian (BAY2433334)
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bayer
Stroke
An Ischaemic Stroke Observational Study
A non-interventional observational clinical study to document the clinical course of patients at 12 months or more following an ischaemic stroke
- Trial name
- NCT03333980
- Where
- 7 sites in United Kingdom
- Volunteers
- 39 people
- Sponsor
- ReNeuron Limited
Ischemic Stroke
Assess the Penumbra System in the Treatment of Acute Stroke
The purpose of this trial is to assess the safety and effectiveness of the Penumbra System as an adjunctive treatment to intravenous (IV) recombinant human tissue plasminogen activator (rtPA)in patients with acute ischemic stroke…
- Trial name
- THERAPY (NCT01429350)
- Testing
- intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Penumbra System
- Where
- 4 sites in United States
- Volunteers
- 108 people
- Sponsor
- Penumbra Inc.
Atherosclerosis, Ischemia
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)
The study is designed to determine whether vorapaxar, when added to the existing standard of care (SOC) for preventing heart attack and stroke (eg, aspirin, clopidogrel) in participants with a known history of atherosclerosis…
- Conditions
- Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident
- Trial name
- NCT00526474
- Testing
- Vorapaxar
- Volunteers
- 26,449 people
- Sponsor
- Merck Sharp & Dohme LLC
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Acenocoumarol for the first…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947985
- Testing
- Rivaroxoban (Xarelto, Bay59-7939), Standard of care
- Where
- Netherlands
- Volunteers
- 208,958 people
- Sponsor
- Bayer
Ischemic Stroke
A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic Strokes
This is a phase 2, multicenter, randomized, double-blind (within dose), placebo controlled, parallel-group, dose-range finding study to evaluate the efficacy and safety of TF0023 spray versus placebo in functional improvement of…
- Trial name
- TF0023 (NCT02785120)
- Testing
- TF0023
- Where
- 24 sites in United States
- Volunteers
- 225 people
- Sponsor
- Techfields Inc
Atrial Fibrillation, Atrial Flutter
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk…
- Trial name
- ARISTOTLE (NCT00412984)
- Testing
- warfarin, apixaban
- Where
- 1,111 sites in United States, Argentina and 39 more
- Volunteers
- 20,976 people
- Sponsor
- Bristol-Myers Squibb
Non-valvular Atrial Fibrillation (NVAF)
A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin
This is an observational study in which data collected from the past of patients with non-valvular atrial fibrillation (NVAF) is studied.
- Trial name
- RENOVATOR (NCT05022758)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Warfarin
- Where
- South Korea
- Volunteers
- 45,000 people
- Sponsor
- Bayer
Intracranial Aneurysm, AVM - Cerebral Arteriovenous Malformation
Postmarket Study of Tarvos Microguidewire in Neurovascular Interventional Surgery
This investigation is to evaluate the clinical effectiveness and safety of the Tarvos Microguidewire in the neurovascular interventional surgery.
- Conditions
- Intracranial Aneurysm, AVM - Cerebral Arteriovenous Malformation, AV Fistula, Acute Ischemic Stroke
- Trial name
- NCT07500155
- Testing
- Tarvos Microguidewire
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Keuro MedTech
Stroke, Acute, Stroke, Ischemic
Observational Study of Efficiency of Cytoflavin, in Patients With Ischemic Stroke Not Receiving Reperfusion Therapy
Stroke remains one of the main socially significant problems in the healthcare in the third millennium. The lethality in persons with history of stroke by the end of the 1st year of disease is high.
- Trial name
- NCT06514976
- Testing
- Cytoflavin
- Where
- 17 sites in Russia
- Volunteers
- 562 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Atrial Fibrillation
Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
To evaluate the safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation (NVAF)and to obtain information on pharmacokinetics and pharmacodynamics (anti-thrombotic potential) in the target population
- Trial name
- NCT00448214
- Testing
- YM150, warfarin
- Where
- 18 sites in Australia, Hong Kong and 8 more
- Volunteers
- 448 people
- Sponsor
- Astellas Pharma Inc
Stroke, Ischemic
An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke.
Uncertainty remains regarding the impact of enteric-coated (EC) aspirin as it relates to the reduction of CV risk. We hypothesize that EC formulation based on the previous report may blunt aspirin response as evidenced by reduced…
- Trial name
- ECASIS (NCT04330872)
- Testing
- Enteric Coated Aspirin Tablet, Plain Aspirin
- Where
- Qatar
- Volunteers
- 42 people
- Sponsor
- Hamad Medical Corporation
Stroke, Acute
Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin
The purpose of the Stroke AF study is to compare the incidence of atrial fibrillation (AF) through 12 months between continuous cardiac rhythm monitoring with the Reveal LINQ™ Insertable Cardiac Monitor (ICM) (continuous…
- Trial name
- NCT02700945
- Testing
- Reveal LINQ™ Insertable Cardiac Monitor
- Where
- 35 sites in United States
- Volunteers
- 496 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Cerebrovascular Accident
Safety Study of a Recombinant Human Plasminogen Activator to Treat Acute Ischemic Stroke.
To evaluate the safety profiles of HTU-PA in patients with acute ischemic stroke.
- Trial name
- NCT00418275
- Testing
- Recombinant Human Plasminogen Activator (HTUPA)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Global Biotech
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.